Maria G. Da Silva

Lisbon, Portugal

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Notable clinical activity of immune checkpoint inhibitors with or without brentuximab vedotin in relapsed or refractory gray zone lymphoma.

Notable clinical activity of immune checkpoint inhibitors with or without brentuximab vedotin in relapsed or refractory gray zone lymphoma.

Journal: Haematologica

Published: April 23, 2026

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Journal: Blood

Published: January 13, 2026

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Journal: Blood

Published: January 13, 2026

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

Journal: Lancet (London, England)

Published: December 23, 2025

Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020.

Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020.

Journal: Haematologica

Published: August 12, 2025

Intensive Treatment in Adult Burkitt Lymphoma with Lymphome Malin B (LMB) Regimen: Excellent Outcomes Despite Substantial Toxicity and Supportive Care Demands.

Intensive Treatment in Adult Burkitt Lymphoma with Lymphome Malin B (LMB) Regimen: Excellent Outcomes Despite Substantial Toxicity and Supportive Care Demands.

Journal: Cancers

Published: August 06, 2025

Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53).

Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53).

Journal: British journal of haematology

Published: July 24, 2025

Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.

Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.

Journal: Leukemia

Published: May 28, 2025

Bridging gaps in clinical trial accessibility and reimbursement for large B-cell lymphoma therapies across Europe.

Bridging gaps in clinical trial accessibility and reimbursement for large B-cell lymphoma therapies across Europe.

Journal: HemaSphere

Published: March 20, 2025

Proteome alterations in peripheral immune cells of DLBCL patients and evidence of cancer extracellular vesicles involvement.

Proteome alterations in peripheral immune cells of DLBCL patients and evidence of cancer extracellular vesicles involvement.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: January 13, 2025

Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients.

Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients.

Journal: HemaSphere

Published: November 19, 2024

Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL.

Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL.

Journal: HemaSphere

Published: July 11, 2024

Showing 1-12 of 44

Last Updated: 09/26/2026